Financial Model & Unit Economics
Bottom line for this section
The HIMS comp ($83 MORPAS, 74% GM, 39% marketing, sub-1-yr CAC payback) reflects scale + brand + a now-defunct compounded GLP-1 economics layer; a single-product peptide startup operating in advertising-restricted channels with no GLP-1 demand anchor cannot rely on those benchmarks — model conservatively at $99-299 ARPU, 50%+ marketing-to-revenue, 10-12% monthly churn (vs HIMS's 70% week-12 retention only achievable with GLP-1 clinical anchor).
Research
The unit economics of a US telehealth compounded-peptide venture in mid-2026 are defined by two regulatory shocks that destroyed the dominant operator playbook: (1) FDA resolved the semaglutide (Feb 2025) and tirzepatide (Dec 2024) shortages, ending lawful 503A/503B bulk-substance compounding of GLP-1s for the mass market, and (2) Hims & Hers — the only public comp at scale — terminated its compounded GLP-1 program in March 2026 after Novo Nordisk severed its Wegovy collaboration. The non-GLP-1 peptides the proposed venture would sell were removed from FDA Category 2 on April 15, 2026 but as of May 2026 are NOT on Category 1 — they sit in regulatory limbo pending the July 23-24 2026 PCAC meeting. HIMS at scale (2.6M subscribers, Q1 2026) shows the achievable mature-state envelope: ~$80 monthly revenue per average subscriber, ~65-74% gross margin (compressing as weight-loss specialty grew share), 36-46% of revenue spent on marketing, sub-1-year payback for 2024 cohort, 70% week-12 retention for weight-loss subscribers — but every layer of those numbers benefits from HIMS' scale, brand, and now-defunct compounded-GLP-1 economics. Per-Rx COGS for non-GLP-1 peptides sits in $30-150/month band per vendor reporting, cold-chain shipping adds ~$50-70 per shipment plus new $8.50/package dry-ice surcharge effective January 2026, and §3-disclosed 5-10% rolling reserves held 90-180 days create proportional working-capital trap.
Key facts
Hims & Hers Health (NYSE: HIMS) reported 2025 full-year revenue of $2.347 billion (up 59% YoY), 2.5 million subscribers (up 13%), monthly revenue per average subscriber $83 (up 28% from $65 in 2024), gross margin 74% (down from 79%), marketing $919.3M (39.2% of revenue), net income $128M, Adjusted EBITDA $318M — establishing the only public-comp baseline.
In Q1 2026 HIMS revenue was $608M (only 4% YoY growth), 2.6M subscribers (+9% YoY), gross margin 65% GAAP / 70% adjusted, marketing 36% of revenue, monthly revenue per average subscriber $80 (down from $85 a year earlier), Adjusted EBITDA $44M (7% margin), GAAP net loss $92M including $33M restructuring — reflects HIMS exiting compounded GLP-1s.
On June 23, 2025 Novo Nordisk publicly terminated its collaboration with Hims & Hers citing 'illegal mass compounding and deceptive marketing'; HIMS stock dropped ~30% the same day, and by March 2026 HIMS settled with Novo, discontinued compounded semaglutide for new patients, and pivoted to distributing branded Wegovy ($299/mo), oral Wegovy ($249/mo), and Zepbound ($399/mo).
FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, ending the §503A and §503B legal basis for routine compounding; FDA has since proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Narrowing exceptions to documented excipient allergies or unavailable dose strengths.
On April 15, 2026 the FDA removed seven peptides (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) from Category 2 following nomination withdrawals, but the removal explicitly does NOT authorize compounding — these substances are not on Category 1, leaving them in regulatory limbo pending FDA PCAC meeting on July 23-24, 2026.
HIMS' 2024 weight-loss specialty achieved 70% subscriber retention at week 12 (vs 42% industry baseline per Blue Health Intelligence) and 85% at week 4 — but that retention was specifically for compounded GLP-1s, where demand is anchored by the medication's clinical effect; non-GLP-1 peptides have no comparable published retention benchmark, and the GLP-1 retention curve is itself unstable post-discontinuation.
Third-party HIMS analyses estimate 2024 blended CAC at ~$89 per subscriber against ~$338 LTV (LTV:CAC ≈ 4:1), with management targeting sub-1-year payback (2024 cohort achieved <9 months); however Q2 2025 marked worst CAC efficiency on record — $188M marketing spend yielded only 73K net new subscribers, implied CAC-per-new-subscriber ~$2,581 (highest ever).
Telehealth retail pricing for compounded semaglutide ranges $129-$299/month (Peak Wellness $129, Eden Health $209, Shed $199, HIMS legacy $199 with 6-month plan plus $39 first month / $149/mo membership); Henry Meds priced flat at $149/mo, compounded tirzepatide retail spans $242-$399/month (OnlineSemaglutide.org $242, Noom Med $299, TrimRx $283-$399, Shed $299-$399).
Compounded non-GLP-1 peptide consumer pricing per vendor reporting: BPC-157 $40-500/month, TB-500 $25/vial to $500/month, sermorelin $79-500/month, CJC-1295 + ipamorelin combo $80-600/month — implying that at a $199 telehealth retail price the gross-margin envelope depends heavily on which peptide is dispensed.
FedEx Priority Overnight base rates start at ~$48.59 for a 5-pound package to Zone 2 and run $50-70 for most small-package zones; effective January 5, 2026 FedEx added a mandatory $8.50/package dry-ice surcharge plus average 5.9% general rate increase, putting realistic cold-chain refrigerated overnight cost at $58-80 per shipment.
Per §4 payment-processing research, specialized high-risk processors charge 2.95-6.0% per transaction with 5-10% rolling reserves held 90-180 days — at $100K monthly volume a 10% reserve held 180 days locks ~$60K in working capital permanently, plus ~$3,500-6,000/month in processing fees; processor termination can hold remaining balance plus reserve for 90-180 days.
MSO ↔ PC ↔ physician revenue flow per Rx is constrained by CPOM and fee-splitting rules: the PC must invoice the patient and pay the prescribing physician a fixed per-consult fee (telehealth-physician rates $15-50 per asynchronous consult, $50-150 per synchronous video visit per industry reporting); the MSO collects a flat or fixed-formula management services fee from the PC NOT a percentage tied to medical decisions.
HIMS U.S. revenue declined 8% YoY in Q1 2026 to $529.9M while rest-of-world revenue surged ~10x to $78.2M — first US contraction since GLP-1 push, directly attributable to discontinuing compounded semaglutide for new patients in March 2026; real-world data point that compounded-GLP-1 revenue base does NOT cleanly migrate to branded distribution at same ARPU when regulatory window closes.
HIMS' 2024 marketing spend was ~$679M (46% of revenue, declining from ~51% in 2023); company targets '1 to 3 points of marketing leverage per annum'. For a single-product peptide startup with no GLP-1 demand anchor, achieving CAC payback under 12 months requires either much lower CAC (owned content / affiliate) or much higher ARPU than HIMS's $80-83/month MORPAS — math does not survive CAC > 6× monthly ARPU with churn at 8-12%/month typical of non-anchored wellness subscriptions.
Tradeoffs
Pricing strategy: low-price subscription vs premium 'concierge'
Low-price subscription ($129-199/mo, Henry-Meds-style)
Pro: Lower CAC payback math; Maximizes addressable market in price-sensitive wellness segment; Easier to sustain through cohort-based ad spend
Con: Compresses contribution margin to single-digit dollars after COGS + cold-chain + processing + reserve + physician fee + support; More vulnerable to COGS shock from FDA peptide reclassification; Higher churn at low price points
Premium concierge ($350-600/mo, clinical-program style)
Pro: Wider contribution-margin envelope to absorb COGS shocks, CAC inflation, processor reserve drag; Premium positioning supports MD-led credentialing, bundled labs; Higher LTV at same retention curve due to higher ARPU
Con: Much smaller addressable market; Premium claims invite more FDA / FTC marketing scrutiny per §7; Conversion drops sharply above ~$300/mo without strong clinical-results substantiation
503A patient-specific vs 503B outsourcing-facility sourcing
503A patient-specific (most retail telehealth peptide today)
Pro: Each Rx patient-specific, no inventory commitment; Smaller batch minimums; pilot at low volume; No 503B registration burden on pharmacy partner
Con: Per-vial cost is higher; thinner contribution margin; Cannot legally advertise specific compounded product; FDA enforcement on 503A peptide compounding is active 2026 risk surface
503B outsourcing-facility sourcing at scale
Pro: Lower per-vial cost via bulk compounding economics; Office-stock dispensing model; Tighter cGMP standards arguably reduce products-liability risk
Con: Requires meaningful Rx volume to justify 503B minimums; FDA closed 503B bulks door on semaglutide/tirzepatide/liraglutide via Dec 2024 / Feb 2025 deadlines; Non-GLP-1 peptides not on 503B bulks list either
"The HIMS comp ($83 MORPAS, 74% GM, 39% marketing, sub-1-yr CAC payback) reflects scale + brand + a now-defunct compounded GLP-1 economics layer; a single-product peptide startup operating in advertising-restricted channels with no GLP-1 demand anchor cannot rely on those benchmarks — model conservatively at $99-299 ARPU, 50%+ marketing-to-revenue, 10-12% monthly churn (vs HIMS's 70% week-12 retention only achievable with GLP-1 clinical anchor)."
Recommendation
Run the CostEstimator widget below with conservative inputs ($199 subscription, $60 COGS + $65 cold-chain + $25 physician + $8 support per Rx, 4.5% processing + 5% reserve carry, 10% monthly churn, $250 CAC) — expect LTV:CAC ratio in 2-3:1 range, which is self-fund-only territory not fundable territory. Cash plan: hold operating runway equivalent to 6 months of revenue to absorb the 180-day rolling reserve trap and dual-MID architecture. Price discipline: don't undercut HIMS's $83 MORPAS at single-product scale; premium concierge $300-500/mo positioning has the contribution-margin envelope to absorb COGS shocks if the July 2026 PCAC outcome reshapes the formulary. Validate CAC payback before scaling: every dollar of marketing should be tracked to cohort, with kill switches if CAC exceeds 6x monthly ARPU.
Steel-manned counter
The strongest counter: the Sequence acquisition by WeightWatchers in April 2023 ($132M cash/equity at ~5.3x ARR on ~$25M revenue) and Eucalyptus Health's acquisition by HIMS for $1.15B in Feb 2026 (at ~2.6x ARR on >$450M ARR) prove that even a sub-scale telehealth peptide venture can exit at meaningful multiples to acquirers seeking subscriber-base purchases. A founder targeting an exit at $25-50M ARR could rationally accept thinner contribution margins in exchange for subscriber-base value at sale.
| Feature | Hims & Hers (HIMS, public, FY2025) | Hims & Hers (HIMS, public, Q1 2026) | Ro (private) | Henry Meds (private) | Mochi Health (private) | Proposed venture (single-product peptide) |
|---|---|---|---|---|---|---|
| Subscription ARPU / month | $83 monthly revenue per average subscriber | $80 monthly revenue per average subscriber | $74-149/mo membership + meds extra | $149 flat for compounded semaglutide | Not disclosed; reported $200-700/mo program range | Modeled $99-299 depending on positioning |
| Gross margin | 74% (down from 79% in 2024) | 65% GAAP / 70% adjusted | Not disclosed | Not disclosed | Not disclosed | Highly sensitive to COGS/shipping at sub-$200 price point |
| Marketing as % of revenue | 39.2% ($919.3M / $2,347.6M) | 36% (down 3pts YoY) | Not disclosed | Not disclosed | Not disclosed | Expect 50%+ given narrow channel set per §7 |
| Subscriber count | 2.5M end of FY2025 | 2.6M end of Q1 2026 | Not publicly disclosed | Not publicly disclosed | Not publicly disclosed | Pre-launch |
| CAC (blended) | ~$89 (third-party 2024 estimate) | Implied $2,581/new sub Q2 2025 peak | Not disclosed | Not disclosed | Not disclosed | Likely $150-400 given §7 channel restrictions |
| CAC payback period | <9 months (2024 cohort) | Sub-12-month target; deteriorating | Not disclosed | Not disclosed | Not disclosed | Must validate before scale |
| Retention (week 12) — weight loss | 70% (vs. 42% industry avg) | N/A — compounded program discontinuing | Not disclosed | Not disclosed | Not disclosed | No GLP-1 demand anchor; lower retention expected |
| Compounded GLP-1 strategy mid-2026 | Active through Mar 2026; settlement with Novo | Discontinued for new patients; pivoted to branded Wegovy ($299) and Zepbound ($399) | Active but facing manufacturer lawsuits | Active; price-leader $149/mo with rising-dose tiers | Active; under manufacturer suit | Not viable — FDA shortage resolution closed legal pathway except documented excipient allergy or unavailable dose |
| Non-GLP-1 peptide menu | Not core | Not core | Not core | Not core | Not core | Core menu (BPC-157, TB-500, sermorelin, CJC/ipa) — but in regulatory limbo until July 2026 PCAC |
Likelihood → / Impact ↑
Open questions
Things this report could not resolve. Send these to your specific advisor.
Actual 503A pharmacy wholesale per-vial rates for non-GLP-1 peptides (BPC-157, sermorelin, CJC-1295, ipamorelin, thymosin alpha-1) at Empower, Hallandale, Tailor Made, and Olympia — rate cards not public.
Email this question to your lawyerDisclosed or implied monthly subscription churn rate for HIMS' non-GLP-1 subscribers (hair / skin / mental-health pre-2023).
Email this question to your lawyerPractical per-Rx physician fee benchmark for a contracted telehealth-prescribing physician in mid-2026 — credible $15-50 (async) / $50-150 (sync) but no single primary-source rate card found.
Email this question to your lawyerHave Ro, Henry Meds, or Mochi disclosed concrete CAC, churn, or contribution-margin numbers post-Novo-vs-Hims fallout?
Email this question to your lawyerFedEx Custom Critical / UPS Healthcare / Quick International specialty cold-chain UPCHARGE over standard FedEx Priority Overnight for refrigerated 2-8°C clinical packaging on a single small-package telehealth peptide shipment?
Email this question to your lawyer